These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3610277)

  • 1. Impairment of drug clearance in patients with diabetes mellitus & liver cirrhosis.
    Narang AP; Dutta DV; Khare AK
    Indian J Med Res; 1987 Mar; 85():321-5. PubMed ID: 3610277
    [No Abstract]   [Full Text] [Related]  

  • 2. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
    Geller LI; Griaznova MV; Bulgakova OS; Kozlova ZP
    Ter Arkh; 1982; 54(2):67-9. PubMed ID: 7071776
    [No Abstract]   [Full Text] [Related]  

  • 4. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
    Oltmanns D; Dennin DE; Pentz R; Siegers CP
    Z Gastroenterol; 1984 Oct; 22(10):598-601. PubMed ID: 6506825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The metabolic clearance rate of antipyrine: a good index for the assessment of the hepatic drug-oxidizing function in cirrhotic patients (author's transl)].
    Miguet JP; Allemand H; Joanne C; Dhumeaux D
    Nouv Presse Med; 1978 Dec; 7(46):4209-11. PubMed ID: 745958
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
    Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
    Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE; Münch U; Meier J
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blood fructose and urinary fructose in diabetes mellitus and in various types of liver damage].
    Mierwa-Homerska S
    Pol Tyg Lek; 1983 Jan; 38(4):109-12. PubMed ID: 6682972
    [No Abstract]   [Full Text] [Related]  

  • 11. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
    Chauhan CK; Nanivadekar SA; Billimoria FR
    Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of diabetes mellitus on drug metabolism in man.
    Daintith H; Stevenson IH; O'Malley K
    Int J Clin Pharmacol Biopharm; 1976 Jan; 13(1):55-8. PubMed ID: 1248919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of free ionized fluoride concentrations of plasma and renal clearance in patients of artificially fluoridated and non-fluoridated drinking water areas.
    Hanhijärvi H
    Proc Finn Dent Soc; 1974; 70 Suppl 1-3():3-67. PubMed ID: 4459950
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
    Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
    Salmela PI; Sotaniemi EA; Pelkonen RO
    Diabetes; 1980 Oct; 29(10):788-94. PubMed ID: 7439538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
    Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: dependence on liver cell failure.
    Fabbri A; Marchesini G; Bianchi G; Bugianesi E; Bortoluzzi L; Zoli M; Pisi E
    Hepatology; 1993 Jul; 18(1):28-35. PubMed ID: 8325618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of diabetes mellitus or liver cirrhosis on total collagen in human skin biopsies.
    Périer C; Baril A; Bayle JJ; Janin J; Frey J
    Biomed Pharmacother; 1984; 38(2):110-4. PubMed ID: 6743772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.